A sustained reduction in IOP was seen in a 12-month interim cohort of patients in an investigational new drug phase 2 clinical trial of the travoprost intraocular implant with the iDose delivery system, Glaukos announced in a press release.
The iDose travoprost is filled with a formulation of travoprost and implanted during a microinvasive procedure. It was studied in 154 patients in the multicenter, randomized, double-masked phase 2 trial, which was designed to evaluate two models of the delivery system with two different travoprost elution rates compared with topical timolol (Read more...)
Uncategorized